WHO Director-General Dr Tedros Adhanom Ghebreyesus speaks about trust and partnerships at the opening day of the World Health Summit in Berlin.

BERLIN — The World Health Organization is kicking off its first European “investment round” Monday at the World Health Summit, seeking to secure backing for its $11.1 billion four-year strategic plan.

The Berlin summit, a marquee event on the global health calendar, draws thousands of health leaders, researchers, and advocacy groups. On the agenda: pandemic preparedness, artificial intelligence in healthcare, climate change’s health impacts and pharmaceutical intellectual property rights.

The fundraising push is the centrepiece of the WHO-led summit. The plan? Putting the world’s leading health agency on a firmer financial footing with long-term, secure, flexible funding commitments from European nations, philanthropies and foundations.

“COVID was really the trigger for this journey towards sustainable financing,” WHO Assistant Director-General Catarina Boehme told Health Policy Watch in an interview Sunday evening. “Member states realised what’s wrong with WHO’s funding – it’s about the resilience of funding, the lack of diversification and the lack of flexibility.”

The publicly broadcast event will feature prominent speakers including German Chancellor Olaf Scholz, philanthropist Bill Gates and Wellcome Trust CEO John-Arne Rottingen, alongside health ministers from France, Germany, Greece, Norway and Switzerland.

Boehme, a German national and former chief of staff to WHO Director-General Tedros Adhanom Ghebreyesus, is spearheading the new funding initiative. The effort aims to find new formulas for voluntary funding critical to filling chronic budget shortfalls left by member states’ regularly assessed contributions.

For decades, member fees have covered only 20%-30% of WHO’s regular budget. A 2022 decision aims to increase that to 50% by 2030, but significant funding gaps remain.

WHO funding drive hits Europe

WHO ADG General Catherine Boehme, (center), now heading up the WHO investment round initiative.

Europe is neither the first nor the last stop for WHO’s pledging drive. On Oct. 7, South East Asian countries pledged $345 million in voluntary donations to the global health agency’s operations during a closed-door event coinciding with WHO’s South East Asia Regional Committee meeting.

Following the Berlin event, investment rounds are planned in WHO’s remaining four regions: the Americas, Eastern Mediterranean, Africa and Western Pacific.

Loosely inspired by successful fundraising drives of multilateral health organizations like The Global Fund and Gavi, the Vaccine Alliance, WHO’s approach, approved by member states in May, appears more restrained.

While The Global Fund’s “replenishment drives” have featured heads of state sharing stages with rock stars to boost visibility, WHO is working through potential donors region by region.

The focus is on broadening the base of member states who supplement their “assessed” contributions and changing the culture of giving to foster long-term funding commitments with fewer restrictions.

‘COVID was the trigger’

WHS draws thousands of attendees worldwide from civil society, academic and government ranks.

“COVID was really the trigger for this journey towards sustainable financing,” Boehme said. “It was through the pandemic that member states realized what’s wrong with WHO’s funding.”

“It’s about the resilience of funding. It’s about the lack of diversification. It’s about the lack of flexibility,” Boehme said, noting that more than 70% of WHO’s funding comes from just 10 donors.

Boehme hopes that pledges obtained at the event and in its aftermath will include fewer “earmarked” donations, which tie funds to specific programs or projects — a common feature of voluntary contributions to the UN health body to date.

“We are super ineffective because 80% of our funding is earmarked,” Boehme said. “It’s really narrowly defined what we can spend it on, which is terrible, for example, for health emergencies. We basically cannot direct our funding where we need it.”

She added that predictability is also a major issue, with 50% of WHO’s voluntary donations made as one-year grants. This leaves the organization heavily reliant on short-term staff “with no job security.”

“It’s not even about elevating the baseline. It’s actually more about making funding more predictable, more flexible,” Boehme said. “Then we can use the baseline to pay for the core stuff we need to then be able to react to emergencies.”

Trust and health

‘There’s no health without trust’ says WHO Director General Tedros

In his opening remarks Sunday evening, WHO Director-General Dr Tedros Adhanom Ghebreyesus, linked the fund-raising drive to the conference theme of “trust”, saying that building trust between WHO and its member state partners is critical to improving the organization’s credible response to fast-evolving disease outbreaks and conflict-driven emergencies.

“Trust itself does not make people healthy, but no one can be healthy without trust,” said Tedros, pointing to examples of outbreaks, from Ebola to the COVID-19 pandemic, where public confidence in advice on issues ranging from safe burial to vaccination was critical to getting diseases under control.

“Strong partnerships – like strong relationships – are built on trust,” he added, saying “Everything we do depends on the trust of the communities we serve, the partners with whom we work, and the Member States who set the global health agenda, and entrust us with the resources to deliver it.”

“At this year’s World Health Assembly, Member States adopted a new and ambitious strategy to save 40 million lives over the next four years: the 14th General Programme of Work,” he added, referring to the objectives of the 2024-2028 budget plan.

“Delivering that strategy requires a strong and sustainably financed WHO, which is why we have launched the first WHO Investment Round, to mobilize upfront the predictable funding we need to do our work over the next four years.

“We know that we are making this ask at a time of competing priorities and limited resources. But as the COVID-19 pandemic demonstrated, when health is at risk, everything is at risk.  Investments in WHO are therefore investments not only in healthier populations, but also in more equitable, more stable and more secure societies and economies.

“They’re investments in the vision countries had when they established WHO in 1948: the highest attainable standard of health for all people, as a fundamental right.”

Image Credits: Stefan Anderson/HPW, LinkedIn.

A laboratory technician at Afrigen in South Africa.

A recent article published by HPW based on research by Matthew Herder and Ximena Benavides made several criticisms and observations about the mRNA programme. HPW asked the mRNA co-leaders, the MPP and WHO, to respond to the issues raised and this is their response. 

The mRNA Technology Transfer Programme, established by the World Health Organization (WHO) in partnership with the Medicines Patent Pool (MPP), was launched in July 2021 in response to the COVID-19 pandemic to address the global inequities in vaccine manufacturing. Its primary aim is to build mRNA vaccine manufacturing capacity in low- and middle-income countries (LMICs), thus bolstering health security through local and regional production.

A key component of the Programme is the South African Consortium, which consists of Afrigen, Biovac, and the South African Medical Research Council (SAMRC). The consortium, with the contribution of other research organizations in South Africa, is responsible for developing an mRNA-based technology platform (with Afrigen focusing on pre-clinical and early clinical scales and Biovac handling late clinical and commercial scales) and vaccine candidates tailored to the needs of LMICs, with the objective being to transfer them to a network of technology recipients called Programme Partners within LMICs.

Alongside the South African Consortium, the Programme brings together a range of international and local partners who are critical players in developing and transferring vaccine technology to LMICs. The initiative receives support from donors such as Belgium, Canada, the European Commission, France, Germany, Norway, South Africa, and the ELMA Foundation.

The Programme’s four primary objectives are:

  1. Establishing sustainable mRNA vaccine manufacturing capacity in regions with limited production ability;
  2. Introducing new technologies and promoting research and development (R&D) in LMICs;
  3. Strengthening regional biomanufacturing capacity through knowledge-sharing and workforce development;
  4. Developing regulatory capabilities to support the approval and distribution of vaccines in LMICs.

 Establishment and structure 

The Programme emerged from a critical need recognized during the COVID-19 pandemic, as it became evident that LMICs lacked the capacity to produce medical countermeasures, particularly vaccines. 

France suggested establishing a fifth ACT Accelerator (ACT-A) pillar to address this gap. Following discussions within ACT-A, and given the urgency of vaccine production, the initiative translated into a Vaccines Manufacturing Taskforce established under ACT-A’s vaccine pillar, COVAX, with three workstreams. Workstreams 1 and 2 focused on addressing immediate challenges, such as supply bottlenecks, while Workstream 3 took on the longer-term goal of establishing vaccine production in LMICs.

Due to its expertise in licensing and legal matters, WHO asked the UN-backed Medicines Patent Pool to co-facilitate Workstream 3. Following guidance from WHO’s Product Development for Vaccines Advisory Committee, Workstream 3 focused on mRNA technology, ultimately evolving into the mRNA Technology Transfer Programme. 

With the completion of Workstreams 1 and 2, the Vaccines Manufacturing Taskforce was sunset, and the Programme moved into WHO’s Access to Medicines and Health Products division.

Every company that applied to the Expression of Interest launched by WHO in November 2021 to be a recipient of mRNA technology through the WHO selection process was accepted, barring any technical issues. In the Pan-American region, the Pan-American Health Organization led its own selection process, resulting in the choice of one company each from Argentina and Brazil. 

All companies were required to have the backing of their respective governments. With two recipients in South America, six in Africa (including Biovac), two in Eastern Europe, and five in Asia, the Programme ensures broad mRNA production capacity across LMICs globally.

Governance

Charles Gore (MPP), Afrigen CEO Petro Terreblanche, Dr Tedros Ghebreysus, Director-General the WHO, Dr. Joe Paahla, SA Minister of Health, and Anne Tvinnereim, Norwegian Minister of International Development, formally launched the mRNA project in Cape Town in April, 2023.

Oversight of the Programme rests with WHO, which regularly engages with its Member States through meetings to provide updates and gather input. Additionally, quarterly meetings are held with Programme funders and civil society.

To assist in decision-making, WHO established the Scientific and Technical Review Committee (STeRCo), which provides advisory support to the WHO secretariat on critical technical matters. The STeRCo consists of independent experts and stakeholders, including representatives of the Civil Society, who guide WHO on areas essential to achieving the Programme’s objectives, such as:

  • Strategic direction, including the evaluation of technologies for implementation and transfer;
  • Pre-clinical and clinical development plans for relevant mRNA technologies;
  • Adherence to regulatory guidelines;
  • Value for money in fund allocation;
  • Other critical issues to ensure the successful execution of the Programme.

From the outset, the South African Government and Africa CDC have been integral members of the STeRCo, ensuring their perspectives are included in decision-making. This inclusive approach is central to fostering local ownership and keeping the Programme responsive to the needs of LMICs.  Additionally, MPP convened an mRNA Scientific Advisory Committee (mSAC), comprising internationally recognized experts in mRNA vaccine development, to provide top-tier scientific input into the Programme.

Knowledge sharing and empowerment of LMIC partners

A cornerstone of the programme is knowledge sharing and empowerment of LMIC partners. For instance, Afrigen and Biovac, both part-owned by the South African government, play a central role in developing and transferring the mRNA technology platform, developed with a specific COVID-19 vaccine variant as proof of concept, to 14 companies across multiple regions. The South African Medical Research Council (SAMRC) shares knowledge with the network of partners on second-generation mRNA technologies and vaccine candidates targeting other diseases.

All partners benefit from MPP’s licensing model, which ensures consistency across the Programme by offering non-exclusive royalty-free licenses in LMICs, allowing equitable access to the developed technologies.

In addition to the core governance framework, it is important to highlight the continuous engagement and collaborative efforts between the partners. These include regular calls with all partners, and participation in significant global conferences, such as the Developing Countries Vaccine Manufacturers Network (DCVMN), and other major conferences.

The partners frequently present their progress during various meetings, including Clinical Study (CS) meetings and Research & Development (R&D) events. Additionally, WHO carries out government engagement missions as an integral part of this collaborative process. These efforts ensure that all stakeholders are aligned and informed of the programmes work.

Role of WHO and MPP in supporting the Programme

The role of WHO and MPP, the co-facilitators of the Programme, is to support and empower. An example of this are the research and development consortia, whose creation amongst the entities involved in the Programme is being supported by WHO and MPP, and each consortium  is each being led by a research organisation also includes one or more Programme Partners.

These consortia are completely autonomous in deciding where to focus their efforts. In addition, as part of the Programme, WHO launched a bio-manufacturing training programme for people in LMICs to ensure availability of skilled local workforce in the manufacturing and regulatory fields to sustain the production of biologic countermeasures both during and between pandemics.

Afrigen CEO Dr Petro Terreblanche and some of her scientific team.

 Licensing and intellectual property (IP) strategies

Because the role of WHO and MPP is to support and empower rather than control, the Programme imposes as few conditions on the participants as possible. The major conditionality is the requirement for partners to license the intellectual property they develop to MPP, allowing MPP to sub-license it to other Programme Partners.

This model, which MPP has used for other products, encourages competition, ensuring affordability while maintaining sustainability for manufacturers. A notable example of this approach is the first-line HIV treatment regimen, which MPP sub-licensed to manufacturers, enabling the Global Fund to procure it at less than $40 per person per year—the lowest price ever achieved for such a regimen. This price reduction was driven by competition and innovation, particularly in manufacturing process optimization.

Technology transfer and capacity building

MPP’s technology transfer team plays a central role in providing technical advice, project management, and oversight during the various phases of technology development and transfer.

While MPP does not engage directly in laboratory work, it facilitates the transfer of expertise, evaluates infrastructure needs, engages with external entities supporting analytical work, and assesses workforce training requirements. A multilateral staggered technology transfer approach was adopted to expedite the process, allowing partners to access essential information as it became available.

This early access provided the Partners with the opportunity to familiarize themselves with the fundamentals of mRNA technology while Afrigen continued its initial development. MPP’s role is to support Afrigen and Biovac in developing the mRNA platform (processes and analytics) and act as an intermediary, fielding numerous requests from partners about facility designs, equipment and material specifications, process descriptions, and troubleshooting. 

By doing so, MPP ensures that Afrigen and Biovac can focus on technology development while still addressing the needs of the manufacturing Partners. This approach has been successful, so far.

Afrigen has now established an mRNA manufacturing platform at a 1 litre IVT scale and initiated the transfer of the technology to Biovac earlier this year by providing an on-site technology platform demonstration. The remaining technology platform demonstrations at Afrigen to the Programme Partners are set to begin in Q4 2024 and continue into 2025.

An Afrigen laboratory technician works on making an mRNA vaccine against SARS-Co-V2.

 Sustaining the Programme

The primary goal of the mRNA Technology Transfer Programme is to ensure that LMICs have the mRNA capacity and capability to respond to the next pandemic. To achieve this, however, it is necessary to keep manufacturing facilities ‘warm’ by producing mRNA products between pandemics. 

Since the timing of the next pandemic is unknown, and there is little appetite for indefinite subsidies, these products must have viable markets and generate a constant stream of adequate revenues. 

This was a critical lesson from WHO’s earlier influenza technology transfer initiative. Just as important to sustainability is the role of government in each of the Programme Partner’s countries. Policies must be adapted to favour the investment being made, and this includes strengthening the National Regulatory Authority, which will require an investment of time and resources. 

Changes in procurement practices across countries and regions may need to be made along with data sharing to estimate demand. Building a robust ecosystem in LMICs is an area of urgent priority. From the outset, Programme Partners and recipient countries were informed that they would need to secure their own financing, as the Programme itself would not be providing funding. 

However, France and Canada made additional funding available for specific countries. This extra funding has not influenced or distorted the Programme’s overall direction. All partners will eventually receive some level of support. However, the extent of this support may vary depending on donor preferences and whether the recipient is a public or private entity.

Additionally, the Programme has not encountered any high-income countries (HICs) unwilling to support the development or transfer of upstream inputs, such as novel lipid nanoparticles (LNPs) and antigens. 

A laboratory technician at Afrigen.

Currently, the Programme is funded until 2026. While additional funding is required to complete the year, the goal is to complete the transfer of technology to the majority of partners by that time. The Programme coordinators are working with partners to develop sustainable business models and explore new funding sources to ensure operations can continue beyond 2026.

A major part of this sustainability strategy is the creation of R&D consortia focused on developing vaccines for diseases relevant to LMICs. These consortia bring together Programme Partners, companies, research centers, and universities to collaborate on the development of vaccines and therapeutics using the mRNA platform. 

So far, four consortia have been established in Southeast Asia, working to develop preventive mRNA vaccines against dengue, Plasmodium Vivax malaria and human hand, foot and mouth disease and a therapeutic human papillomavirus mRNA vaccine. 

Ongoing R&D work is also focused on RSV, Rift Valley Fever, gonorrhoea, HIV, and tuberculosis. In a recent meeting in Brazil, three more consortia were proposed, focusing on influenza (pandemic and seasonal), leishmaniasis, and novel lipids.

Conclusion

The mRNA Technology Transfer Programme is a landmark initiative aimed at addressing the inequities in global vaccine production by empowering LMICs to develop and produce their own vaccines. 

Through a combination of technical support, knowledge-sharing, and innovative licensing strategies, the Programme is creating a sustainable model for mRNA vaccine production that will enable LMICs to respond to future public health challenges. 

As it looks beyond 2026, the Programme remains focused on ensuring its long-term viability and expanding its impact across LMICs, contributing to global health security for the years to come.

Image Credits: WHO, WHO , Kerry Cullinan, WHO.

In Dwazark Community, Freetown, Sierra Leone, students at St. Augustine School receive the HPV vaccine to protect them against cervical cancer.

On the International Day of the Girl Child, new HPV vaccine is hailed as a lifesaver

Across Africa, too many women are still dying from cervical cancer – a disease that is almost entirely preventable with HPV vaccines.  

For too long, these vaccines have been out of reach for many girls across the continent.  

But in early October, the World Health Organization (WHO) announced a decision that will help countries around the world reach more girls with these lifesaving vaccines.

The decision adds a new vaccine, Cecolin, that can be given in just one dose – in addition to two existing vaccines– helping countries vaccinate more girls with fewer resources. 

This could have a particularly big impact in Africa, which is home to 19 of the top 20 countries with the highest burden of cervical cancer. In many of these countries, access to screening and treatment for cervical cancer is limited. 

Critical preventative tool

Most cases of cervical cancer are treatable, but too many women don’t know they have cancer until it’s too late. Even when it’s caught early enough, these women may not live close enough to a hospital with the resources and specialists needed to treat cervical cancer, let alone have the funds to afford care. 

That’s why vaccines are a critical preventative tool. Vaccines that protect girls against HPV infection – the main cause of cervical cancer – are highly effective at preventing them from developing cervical cancer later in life.

For years, organizations like PATH, Gavi, the Vaccine Alliance and many others have strived to raise awareness about how HPV vaccines can improve the lives of the people in their communities.  

Thanks to these efforts, and the commitment of many African leaders to protect future generations of women against cervical cancer, we’ve made impressive progress on HPV vaccination. In 2023, 40% of girls in the African Region had received a dose of HPV vaccine, compared to only 21% in 2020. Still, vaccine coverage rates are far below what they should be if we are going to eliminate cervical cancer by 2030.  

More choice to address supply shortages

A young girl receives a single dose of HPV vaccine at Lisawo primary school in Chiradzulu, Malawi.

While many African countries are ready to introduce HPV vaccines or scale up programs, vaccine supply shortages are hindering progress.  

Every day that vaccination programs are delayed places more girls at risk of cervical cancer as they grow up. Since HPV vaccination programs mainly target girls aged 9-14, delays mean that many girls will miss out on lifesaving protection if countries are not able to reach them within this narrow window.  

Additional vaccine supply that can be given on a one-dose schedule can help countries reach more girls with these lifesaving vaccines.  

Previously, HPV vaccination has followed a two-dose regimen, but according to WHO, just one dose is sufficient to protect against cervical cancer.

Nearly 60 countries have decided to follow a one-dose schedule, from high-income to low- and middle-income countries. Countries that made the switch in 2023 increased HPV vaccine coverage by an average of 8%, vaccinating an estimated six million additional girls. 

African countries are leading efforts that could protect more girls by using a one-dose schedule – 17 African countries have already switched. 

WHO’s decision offers a new path for countries that want to introduce HPV vaccines or expand their programs using a one-dose schedule. This could be especially helpful for countries supported by Gavi, the Vaccine Alliance, which helps governments by co-financing immunization programs and helping them procure vaccines for subsidized prices. Now all three HPV vaccines on the Gavi menu can be used with a one-dose schedule. 

 Having a variety of HPV vaccines to use with a one-dose schedule means countries don’t have to wait as long to introduce vaccines.

If one manufacturer has issues, like delays or shortages, countries can rely on other options to keep HPV vaccination programs running smoothly, ensuring girls don’t have to miss out on the opportunity to get vaccinated.

Several countries in Asia and Africa are already considering what WHO’s decision could mean for their HPV vaccination efforts.   

WHO’s decision is more than just an update to a technical document; it is an opportunity for African countries to commit to safeguarding the health and future of the next generation of women.

Cervical cancer elimination is within reach, in Africa and beyond. By seizing this moment and embracing the one-dose HPV vaccine schedule, governments and leaders can ensure that no girl is left behind.

Cathy Ndiaye is Director of HPV Vaccine Programs at PATH. PATH is a global nonprofit dedicated to achieving health equity. With more than 40 years of experience forging multisector partnerships, and with expertise in science, economics, technology, advocacy, and dozens of other specialities, PATH develops and scales up innovative solutions to the world’s most pressing health challenges.

Image Credits: Gavi, Nadia Marini/ MSF .

Dr Jean Kaseya, Africa CDC Director General, accused the US of creating panic around Rwanda’s Marburg outbreak.

The Africa CDC has slammed the US government’s recent Level 3 travel advisory for Rwanda as unfair and baseless, arguing it undermines Rwanda’s proactive efforts to contain a Marburg outbreak. With rapid testing, vaccinations, and coordinated emergency response measures in place, Rwanda’s leaders insist the country poses no international threat and warn that travel restrictions could stoke panic and discourage transparency in future health crises.

Dr Jean Kaseya, Director General of Africa CDC, called the US decision “unfair” during a press briefing Thursday, accusing Washington of creating unnecessary panic. On October 7, state department increased the advisory level from 2 to 3, with the caveat to “reconsider travel in Rwanda due to an outbreak of Marburg Virus Disease”.

New US travel advisory on Rwanda, issued 7 October 2024.

Kaseya emphasized that Rwanda had taken a transparent and comprehensive approach to controlling the Marburg outbreak, which was declared on September 27.

“Rwanda collaborated with all partners, including the U.S., to show that there is no risk of spreading this disease,” he stated. He pointed to the country’s proactive measures, such as stringent screening processes at Kigali International Airport, effective contact tracing, and cross-border surveillance, as evidence of Rwanda’s commitment to preventing international transmission.

The press conference also featured remarks from Rwanda’s Minister of Health, Dr. Sabin Nsanzimana, who detailed the country’s rapid response efforts, which include intensive testing, vaccination campaigns targeting healthcare workers and high-risk groups, and the use of multiple therapeutic options. “We are working closely with partners across the world… although this is the most dangerous virus in the world, we came up stronger to respond,” said Nsanzimana.

Marburg outbreak, mapping both cases and location of contacts as of 2 October.

Rwanda has so far confirmed 58 cases of Marburg virus disease, with a case fatality rate (CFR) of 22%.  While that is four to five times higher than the average CFR of COVID in the first six months of the pandemic, it is significantly lower than the fatality rate of previous Marburg outbreaks in other parts of the Africa region, Nsanzimana contended.

Historically, the case fatality rate of Marburg has averaged 50%, according to WHO, although it has varied between 24-88% in different outbreak contexts.  The virus, which causes haemorrhagic fever, is in the same family as the virus that causes Ebola virus disease. Bats are regarded as a key virus reservoir.  

Rwanda’s use of advanced therapeutics and vaccine trials

Nsanzimana attributed the relatively low fatality rate to the country’s early detection of cases, rapid isolation protocols, and the administration of supportive treatments, such as antiviral drugs and monoclonal antibodies, administered to critically ill patients.

“The earlier you detect, the better the outcome,” he noted, underscoring the importance of prompt diagnosis and immediate response.

Marburg Rwanda
Rwandan Minister of Health, Sabin Nsanzimana speaking at the Africa CDC press briefing on Thursday.

Rwanda has also already administered over 200 doses of an investigational Marburg vaccine developed by the Sabin Vaccine Institute, he revealed. The vaccination campaign, which began this week, prioritizes healthcare workers and individuals in close contact with confirmed cases. The minister announced plans to expand the vaccination effort to additional high-risk groups in collaboration with international partners. “Our aim is to vaccinate as many people at risk as quickly as possible,” he added.

Despite the positive strides made, Nsanzimana acknowledged the need for more vaccine doses and indicated that Rwanda is actively working to secure additional supplies to protect healthcare workers and communities.

Rwanda has adopted an open-label approach to the vaccine trial to expedite protection for at-risk groups, Nsanzimana said. But due to the deadly nature of the disease, the initial protocol does not include a delayed-arm trial, but plans are in place to expand the study and consider alternative methodologies as more data becomes available.

“Our focus now is on saving lives and preventing transmission. We can explore more complex trial designs as we move forward,” he said.

Criticism of travel bans

Amid growing concerns about travel restrictions, both Kaseya and Nsanzimana argued that imposing travel bans is counterproductive during outbreaks, as they may deter transparency and international collaboration. “Let us be guided by facts and science,” Nsanzimana stated, pointing out that Rwanda’s efforts to contain the virus should be viewed as a model rather than grounds for punitive measures. Kaseya added that the country’s centralized emergency response system and comprehensive cross-border surveillance demonstrate its preparedness and should be encouraged, not penalized.

The Africa CDC chief emphasized that travel advisories based on limited evidence could harm not only the affected country but also the global community by discouraging other nations from reporting outbreaks in a timely manner. He disclosed that following discussions, the U.S. government had agreed to consult with Africa CDC before issuing any future travel-related advisories regarding the continent. “We need to ensure that decisions are based on evidence and consultation with local health authorities,” Kaseya said.  US officials have also praised Rwanda’s rapid outbreak response, in comments like one from Rwanda’s US Amassador Eric Kneedler on X, who called it a “model” for the region. 

Strengthening cross-border cooperation and surveillance

Kaseya and Nsanzimana also highlighted the need for cross-border cooperation and surveillance efforts aimed at containing the Marburg virus and preventing regional spread. Kaseya announced that Africa CDC is deploying rapid diagnostic testing and bolstering surveillance capabilities in neighboring countries to ensure that any potential cases are quickly identified and isolated. He revealed that more than 5,000 test kits have already been distributed to high-risk areas, and plans are underway to establish rapid testing stations at key border points.

Rwanda also revealed it has set up a centralized emergency response center that integrates all relevant services, including health workers, the military, police, and ambulance services. This coordinated approach, the minister said, allows for rapid deployment of medical personnel and other resources across the country. “The mechanism they put in place is impressive,” Kaseya said. “When a call comes in, they can locate an ambulance anywhere in the country, not just in Kigali, and deploy personnel quickly.”

Ongoing mpox outbreak: a public health concern

Roundup of mpox cases in the African region.

At the briefing, Kaseya also stressed that the ongoing mpox outbreak remains a significant public health issue across the continent, with 3,186 new cases and 53 deaths recorded during the last week of September across Africa. The Democratic Republic of Congo (DRC), Nigeria, Uganda, and other nations are grappling with the virus, which continues to spread due to limited testing capabilities and low vaccination rates. Neighboring Republic of Congo, reported its first mpox case in the capital of Brazzavile, after six weeks of no case reports.. 

The lack of sufficient laboratory infrastructure was highlighted as a major challenge in countries like Liberia and the DRC, where low testing rates hinder accurate tracking of the outbreak. “The outbreak is still there, still increasing, and we need to stay focused to stop it,” Kaseya warned, urging affected countries to prioritize improving laboratory capacity and access to diagnostics.

Mpox vaccination campaigns underway in DRC

During the briefing, officials provided updates on the mpox vaccination rollout in the DRC, where a campaign targeting high-risk regions commenced on October 5. The first phase has seen 1,654 individuals vaccinated in DRC’s eastern regions such as North Kivu, South Kivu, where M23 militias control much of the territory. Kaseya acknowledged the logistical challenges faced during the rollout, particularly the distribution of vaccines to remote and conflict-prone regions. He commended the DRC government for prioritizing vaccination in areas with the highest burden of cases and reiterated Africa CDC’s commitment to supporting similar efforts in other affected countries, including Nigeria and the Central African Republic.

Calls for solidarity

Calling for greater regional and global solidarity in the fight against disease outbreaks, Kaseya and Nsanzimana both emphasized that health crises in one region can quickly affect others. 

In addition to pressing the US to lift its Level 3 travel advisory, the Africa CDC director repeated his commitment to working with the WHO and other partners to strengthen outbreak response systems across the continent.

This includes pushing for the finalization of a global pandemic agreement that would accelerate knowledge transfer, ease intellectual property restrictions on developing countries’ use of new and patented drug formulations, and facilitate local manufacturing of vaccines and therapeutics in Africa.

“The travel ban is not a solution,” Kaseya stated, calling for continued collaboration and evidence-based decision-making. “Let us continue to work in solidarity. We are one planet, and we must face these challenges together.”

Image Credits: Africa CDC, US State Department , WHO, Africa CDC .

A traditional brick factory in Tozeur, southern Tunisia. In Africa and South Asia brick making and waste burning are major sources of air pollution.

Governments worldwide allocated almost $700 million (15%) more international development aid to fossil fuel expansion in 2022 than to projects improving better air quality – which typically also promote green energy and reduce climate emissions, according to a new report from the Clean Air Fund.

This marks a sharp reversal from 2021 when international aid from governments, bilateral development agencies, and multilateral development banks for clean air initiatives briefly overtook the investments in fossil fuel development.

The latest data also shows aid for fossil fuel expansion has more than quadrupled, rising from $1.2 billion to $5.4 billion in just one year.  Although investments in clean air projects nearly doubled, from $2.4 to $4.7 billion, the net result was that fossil fuel investments regained the historic lead once more – in terms of global development priorities. 

International aid for fossil fuel development as compared to projects that improve air quality over five years.

The new CAF analysis hones in on international aid funding that is targeted to addressing outdoor air pollution in comparison to fossil-fuel prolonging investments, says Merel Krediet, one of the report’s authors. “This outdoor air quality funding hones in on projects that explicitly target air pollution,” she said.

A separate analysis looks at climate investments in clean energy and transport systems that may  have implicit air quality co-benefits – even though air quality is not cited as a project objective.  On a brighter note, this latter category may in fact be quite large, amounting to as much as $27 billion in 2022, and $94 billion between 2018-2022, according to the CAF analysis. The assessment was based on review of an OECD investment data base, and other climate investment data.

Even so, Jane Burston, CEO of the Clean Air Fund (CAF), described the “shocking increase in aid funding to fossil fuels” as  “a wake-up call”. 

“The world cannot continue down this path of propping up polluting practices at the expense of global health and climate stability. We need to see a drastic shift towards supporting clean air initiatives and debt-free aid to communities who need it most,” said Burston.

CAF warns that the problem is compounded by the structure of the clean air aid, with 92% of funding towards air quality initiatives provided as loans, while only 6% is allocated as grants. 

“This loan-heavy model would place an unsustainable burden on low-income, heavily polluted countries that cannot afford to take on additional debt,” said CAF in a statement on Thursday.
“This stands in stark contrast with other areas of international development funding  such as healthcare and education. On average, 63% of official development assistance is funded as grants.”

Significant proportion of deaths from air pollution are attributable to fossil fuel emissions

Smoking chimneys air pollution
Power plant running on fossil fuels emits air pollution over a city skyline. A large proportion of air pollution-related deaths are due to fossil fuel emissions.

A significant proportion of the estimated 8.3 million annual deaths caused by outdoor air pollution globally are attributable to fossil fuel emissions – and over half according to some of the most recent estimates. Despite this, governments continue to channel aid into fossil fuel prolonging and expanding projects, while clean air initiatives receive less than 1% of available ODA funding, overall. 

Toxic air also carries immense economic costs, with the combined impact of premature deaths, lost productivity, and healthcare expenses for diseases like cancer, heart disease, and dementia running into trillions of dollars each year. The World Bank estimates this “dirty air tax” drains around 6.1% of global annual GDP.

Report on ‘dirty air’ ODA investments come ahead of COP29 discussion of new goals for climate finance

These findings come just ahead of the upcoming UN Climate Conference (COP29) in Baku, 11-22 November, where negotiators are expected to focus significant attention on climate finance goals.  At the conference, leaders and negotiators will reassess international funding strategies and attempt to hammer out a “New Collective Quantified Goal (NCQG)” for accelerating climate finance. 

CAF and other clean air advocates want to seize the moment to secure commitments on increased air quality funding –  with an emphasis on providing grants instead of loans to already heavily-indebted low- and middle income countries.”

There is also a need to address the significant inequalities seen in funding for low-income countries, particularly in sun-rich regions of Africa and the Middle East, and some middle- or upper-middle-income states in Asia, Europe and Latin America.

“There are wide ‘funding deserts’ because funding is spread unevenly across regions,” the report states. For example, outdoor air quality funding for every country in Africa and the Middle East was only a third of the funding channelled to one Asian country, the Philippines ($1.5 billion versus $4.7 billion from 2018 – 2022).”

Over the same period, low-income countries such as Chad and Somalia receive much less funding than upper middle-income countries such as Serbia and Costa Rica: $2 versus $73 of overall air quality funding per capita.

 “Even as countries pledge to reduce their emissions, increase their climate change ambitions and transition away from fossil fuels, the figures tell a different story,” said Adalberto Maluf, National Secretary of Urban Environment and Environmental Quality in Brazil,” in a comment on the report’s findings. 

“International public funding does not come close to meeting the scale of the challenge or unlocking the significant opportunity of investment in air quality. What funding exists often does not reach the most affected geographies, communities and vulnerable people. It doesn’t have to be this way. 

“Brazil, as G20 chair and the incoming COP Presidency, is proud to be championing another vision for the planet: one where humans and nature co-exist in harmony, where we respect the environment we are blessed with, and where economic prosperity doesn’t come at the expense of our health and wellbeing.”

Barbara Buchner, Global Managing Director of Climate Policy Initiative, which co-authored the report, said: “Air pollution and climate change are driven by the same root causes, and share the same solutions. Directing limited public funds towards fossil fuel projects and subsidies is locking in harmful emissions for decades to come. International aid and climate finance should prioritize initiatives that improve air quality, delivering significant health, economic, and climate benefits.”

  • Elaine Ruth Fletcher contributed reporting to this story.

Image Credits: INGImage, WHO/Diego Rodriguez, Clean Air Fund.

(L-R) WHO’s Yvan J-F. Hutin, Mateusz Hasso-Agopsowicz and Martin Friede, launch new report quantifying how vaccines could reduce deaths from drug resistant pathogens.

Better use of existing pneumonia and typhoid vaccines as well as new TB and pneumonia vaccines that are currently in clinical trials, could save over half a million deaths annually from drug resistant pathogens that don’t respond to antibiotics, according to a new WHO report on how vaccine strategies can reduce antimicrobial resistance (AMR).

And over a longer term, better use of existing vaccines as well as the development of new vaccines against 24 deadly pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address AMR, according to the report, published on Thursday.

“Antimicrobial resistance in reality, is a sort of a race between the microbes or the bugs that are getting smarter to evade the antimicrobials, with the antibiotics and the new medicines,” said Yvan J-F. Hutin, Director of Surveillance, Prevention and Control, AMR Division, WHO, at a press conference on Thursday discussing the report.

Along with more judicious use of available drugs, preventing diseases from ever occurring is a critical AMR strategy, he added. And along with better water, sanitation and hygiene, vaccination is an important, but oft-overlooked AMR prevention tool.

“Within the prevention pillar, vaccination is really important,” Hutin said. That means, “using the vaccines that we have today to increase the coverage, and pushing the vaccines that are close to the finish line, in terms of research and development, like TB, and having the vision to say that for certain pathogens, certain microbes, we don’t have the vaccine yet, but it would make a lot of sense to have this these vaccines.”

Prioritizing vaccine development to prevent AMR deaths, as well as deaths from the disease

Guatemalan infant immunized against Haemeophilus influenze (Hib) – wider Hib vaccination can help combat development of AMR down the road.

“We’ve known for many years that vaccines could play a role in controlling or contributing to the control of antimicrobial resistance, but we haven’t, up until today, been able to say which vaccines and what the impact really could be,” added Martin Friede, Head of the Product & Delivery Research team, within WHO’s Department of Immunization, Vaccines and Biologicals.

“Vaccines have been developed for the last 50 years based on the prioritization,.. of deaths that happened due to that pathogen,” he added.  But that ignored the ancillary effect of pathogen drug resistance when people became ill, and antibiotic treatments failed. “This latest report, however, adds in the element of avoidable deaths from drug resistant pathogens. So now we have a new metric against which we can incorporate into our prioritization methodologies and say, well, not only can we prevent deaths due to the pathogen, but we can prevent antibiotic use.

“We have a good start citing point which to say, these are the vaccines, these are the pathogens where we would have the greatest impact,” on reducing AMR.

There are an estimated 1.13 million deaths annually due to drug resistant pathogens – and more than five million deaths overall are attributable directly indirectly to AMR, according to the latest WHO research.

The report estimates that wider use of already available vaccines against Haemophilus influenzae type B (Hib), a bacteria causing both pneumonia and meningitis, as well as typhoid vaccines could avert up to 106 000 of the deaths annually associated with the development of AMR from antibiotic use when unvaccinated children and adults become ill.

Benefits of wider use of available vaccines, in terms of AMR-related deaths, illness and disability avoided.

Every year, vaccines against Streptococcus pneumoniae could save 33 million antibiotic doses, if the Immunization Agenda 2030 target of 90% of the world’s children were vaccinated, as well as older adults. Vaccines for typhoid could save 45 million antibiotic doses, if their introduction was accelerated in high-burden countries.

And wider application of brand new malaria vaccines now being rolled out, could save up to 25 million antibiotic doses, which are often misused to try to treat malaria, which is caused by the Plasmodium falciparum parasite and other related strains, not a bacteria.

Tuberculosis vaccines would make a major dent in AMR deaths

Health worker visits a patient’s home in Peru to provide TB treatment. MDR-TB is a growing problem making many drugs ineffective for treatment.

TB vaccines could have the highest impact once experimental vaccines  now in clinical trials are approved and widely available, the report finds.  That’s a particular priority given the widening arc of multi-drug resistant forms of TB. Administration of 1.2-1.9 billion antibiotic doses could be averted – a significant portion of the 11.3 billion doses used annually against the diseases covered in the report. Nearly 200,000 more deaths associated with AMR could thus be averted annually.

AMR related deaths, illness and disability that could be avoided from vaccines in late-stage R&D.

Further down the line, vaccines for other deadly pathogens such as Klebsiella pneumoniae, in early stage development could save several hundred thousand more lives, once they are available.

Vaccines could significantly reduce the substantial economic costs of AMR

Globally, the hospital costs of treating resistant pathogens evaluated in the report are estimated at US$ 730 billion each year. If vaccines could be rolled out against all the evaluated pathogens, they could save a third of the hospital costs associated with AMR, the report’s authors also concluded.

“The actual cost of treating these infections is incredibly high, $730 billion every year,” Hutin said. “And what we have found that if we put together all the vaccines that we had evaluated, if we have a scenario that they could be widely used, that reaches those people who need these vaccines, that could avert up to a third of these costs, so quite a large, substantial, quite a large proportion that could contribute to reduction of AMR.”

 

Image Credits: Twitter:@WHO, UNICEF 2024 , WHO , WHO PAHO.

Heavy metals from bombs, such as those Russia is using against Ukraine, are poisoning environments in conflict zones and fueling AMR.

Conflict is a “bio-incubator” of anti-microbial resistance (AMR) yet this is not being recognised or addressed sufficiently, according to Professor Richard Sullivan.

Drug-resistant pathogens thrive in war wounds that are treated in sub-optimal conditions and in environments contaminated by heavy metals from bombs, said Sullivan, who is co-director of the Centre for Conflict and Health Research at King’s College in London.

The risk is huge with around 30% of the global population – 2.4 billion people – currently living in conflict zones, Sullivan told an event hosted by the Geneva Graduate Institute’s Global Health Centre on Wednesday.

Sullivan, who is a surgeon, said he frequently saw patients with dirty shrapnel wounds that took a long time to heal.

“Studies of surgical site infections in most conflict situations found that 70-80% are contaminated with multi-drug-resistant organisms,” he added.

Current conflict – Gaza, Sudan and Ukraine – involves “the increasing use of heavy munitions, and fighting in built-up areas”, which is causing “extraordinary toxification of the environment”, said Sullivan.

“Every single day, about 5,000 to 6000 155 millimetre shells are dropped on Ukrainian or Russian lines. These contain about 10 kilograms of RDX TNT and they contaminate the grounds with heavy metals – and that is just the shells, never mind all the propellant contamination that’s going on from the other types of weapons,” said Sullivan.

These heavy metals cause cell mutations in pathogens that help to drive AMR within the environment. 

Dr Kefas Samson from the WHO’s AMR Division said that the impact of AMR – estimated by The Lancet to have caused five million deaths in 2019 – was likely to be under-estimated because it is hard to collect data in war zones.

Meanwhile, Sullivan added that there were a “lot of implementation gaps” to prevent AMR in wars zones, including better training of health workers to “debride wounds” (remove dead and infected flesh), and provision of kits for infected wounds.

Implementing the UN Political Declaration

Despite the huge role of conflict in AMR, this is barely acknowledged in the United Nations Political Declaration on AMR adopted at the High-Level Meeting on AMR last month.

What the Declaration does do, however, is empower the Quadripartite Alliance – the Food and Agricultural Organisation (FAO), World Health Organization (WHO), World Organisation of Animal Health (WOAH) and the UN Environment Programme – to oversee the implementation of the declaration.

WHO’s Samson said that the Quadripartite’s priority is to support member states to deliver on the declaration – the most concrete aim of which is to reduce AMR deaths by 10% by 2030.

The declaration also charges the Quadripartite with setting up an independent panel to conduct research on AMR by the end of 2025, but the mechanics of this still need to be worked out with member states, said Samson.

No targets for ‘contentious issues’

Member states declined to set targets for certain “contentious issues” because they asked for evidence, added Samson – something that the independent panel needs to address.

A huge gap in the declaration is the failure of member states to commit to a target on reducing the use of antibiotics in the agricultural sector – where 80% are consumed.

“There are commitments in terms of strengthening global governance, there are commitments in terms of financing. There are commitments for health sector targets, for the animal health sector, health sector targets, and agriculture and the environment,” said Samson.

He added that, unlike geopolitical difficulties hampering other multilateral negotiations, there was “some unanimity within the international community and member states to see AMR as a real threat to global health, which requires very urgent actions”.

Ambassador Matthew Wilson from Barbados

Saudi Arabia hosts a Global High-Level Ministerial Conference on AMR on 15-16 November to discuss the implementation of the declaration, and how to raise the $100 million target to assist countries to develop plans to mitigate AMR.

However, Barbadian Ambassador Matthew Wilson described this amount as “modest”, and likely to be just enough to “catalyze the achievement of at least 60% of countries having achieved funded plans by 2030”.

Damien Somé from the Global Antibiotic Research & Development Partnership (GARDP) said that another massive challenge is the “dry pipeline” – only a handful of pharmaceutical companies are investing in finding new antibiotics.

Substantial investment was needed in R&D to find new antibiotics, added Somé.

Image Credits: UNDP.

Helen Rochford-Brennan
Helen Rochford-Brennan

Helen Rochford-Brennan, a 72-year-old Irish woman living with Alzheimer’s, was first diagnosed at 57, with a more complete diagnosis following five years later. At the time, there were no life-enhancing medications, leaving her to face the grim reality of her brain’s gradual decline, enduring what she described as “many dark days.”

“Imagine having a new medication,” Rochford-Brennan said. “My quality of life when I was diagnosed would have been improved. Right now, I have to work really hard to make my life joyful.”

Since her diagnosis, Rochford-Brennan has become a vocal advocate for early detection and access to transformative treatments for people with dementia. She told Health Policy Watch that if existing treatments aren’t approved across all OECD countries or remain available only to the wealthy, it would constitute a human rights violation.

“I need to know that everyone is going to have access,” she emphasised.

Alzheimer’s currently affects over 55 million people worldwide, costing the economy more than $1.3 trillion each year – or more than $15 trillion in a single decade. By 2050, the number of people with Alzheimer’s is expected to nearly triple.

“The world has never thought of the brain as an organ of the body that should be subject to health prevention and research,” said George Vradenburg, founding chair of Davos Alzheimer’s Collaborative (DAC). “The world needs to focus on brain health because it is so central to so much cost and suffering around the world.”

Davos Alzheimer’s Collaborative Founding Chairman George Vradenburg
Davos Alzheimer’s Collaborative Founding Chair George Vradenburg

In 2013, the G8 (now G7) pledged to stop Alzheimer’s by 2025, with a goal to make disease-modifying treatments widely accessible by then. As 2025 approaches, there has been significant progress in early detection, expanding research, and developing therapies. However, DAC stressed in a statement that more needs to be done to ensure fair access to these treatments worldwide, along with greater global investment to tackle this growing health crisis.

To advance these efforts, DAC, along with the European Brain Council, the Global CEO Initiative on Alzheimer’s Disease, the Associazione Italiana Malattia di Alzheimer, and Fondazione Prada, hosted a side event at the G7 Health Ministerial Meeting in Italy. It focused on accelerating cooperation in research, healthcare readiness, and access to innovative treatments.

During the event, organisers called on G7 leaders to address the urgent global challenge of Alzheimer’s and dementia by taking bold steps to ensure widespread and equitable access to life-extending therapies and the latest innovations.

The choice to hold the event in Italy was significant, noted Vradenburg, as Italy has the second-oldest population in the world. By 2050, more than a third of its people will be 65 or older. Currently, 44% of Italians in that age group report memory loss or other cognitive issues as major problems.

George Vradenburg, founding chairman of Davos Alzheimer's Collaborative, speaks at an event in Italy on October 8, 2024.
George Vradenburg, founding chair of Davos Alzheimer’s Collaborative, speaks at an event in Italy on 8 October, 2024.

The event brought together global health ministers, leaders in public health, and experts in dementia and Alzheimer’s. Key participants included OECD Deputy Secretary-General for Health Yoshiki Takeuchi, Charlotte Refsum from the Tony Blair Institute (TBI), UK Dementia Task Force Co-Chair Hilary Evans, US White House Global Health Security Coordinator Stephanie Psaki, and Japan’s Counsellor for Dementia Policy Planning, Yoshimasa Tosaka.

“OECD countries must lead by example by placing dementia higher in the policy agenda,” Takeuchi emphasised. “We must work together to address diagnosis challenges, improve quality of care and support efforts in monitoring outcomes for people with dementia, while continuing to promote research and development for innovative treatments which make a difference in the lives of people with dementia.”

At the event’s conclusion, the partners issued five specific calls to action for G7 governments:

  • Expand global and cross-sector collaboration: Strengthen partnerships between governments, private sectors, scientific communities, philanthropic organisations, and others to foster innovation in dementia research.
  • Invest in healthcare system preparedness: Equip healthcare systems with the resources and capabilities needed to use the latest tools, from cognitive screening and early detection to accurate diagnosis and effective treatment and care.
  • Improve early detection and diagnosis: Build the capacity to detect cognitive impairment early and provide accurate diagnoses, utilising blood-based biomarkers and other technologies starting at the primary care level.
  • Accelerate Alzheimer’s treatment development and delivery: Speed up the creation and distribution of therapies, including new disease-modifying drugs and immunotherapies.
  • Promote global research, access, and equity: Conduct research across diverse populations and develop strategies that work for countries at all resource levels.

A growing global challenge

Alzheimer’s is a neurodegenerative disease that worsens over time, starting with physical changes in the brain, such as the build-up of toxic amyloid plaques, which can occur up to 20 years before symptoms become apparent. Currently, it can take up to two years for a person to receive a diagnosis, and many countries still lack access to the latest diagnostic tools for detecting cognitive impairment.

New treatments are emerging. FDA-approved drugs like Leqembi, for mild dementia, and Kisunla, for early-stage Alzheimer’s, are now available in countries such as the US, UK, Japan, Hong Kong, the UAE, China, and Israel. However, European regulators have rejected both drugs, leaving most European citizens without access.

“Science and industry are starting to deliver groundbreaking, disease-modifying therapies, and more are on the way,” said Vradenburg. “Now we need to ensure these innovations reach the families who need them.”

He urged G7 nations to lead the way by boosting Alzheimer’s research funding and developing healthcare models that ensure early detection, diagnosis, and treatment are universally and equitably available to all, regardless of income.

Vradenburg also criticised the European Medicines Agency for rejecting the drugs, pointing out that, according to the European Commission, over 20% of the EU’s 448.8 million people are 65 or older.

“Decisions about these medications should be made between patients and their doctors, not by bureaucrats in Brussels,” he said, referencing concerns over potential side effects. “Patients should be informed of the risks and benefits and decide for themselves—not the government.”

Push for preventative healthcare

At the event, TBI’s Charlotte Refsum advocated for greater investment in preventative healthcare. She told Health Policy Watch that while people in developed countries are living longer, they aren’t necessarily living in good health. This leads to a growing financial strain on healthcare systems, with increasing costs and a shrinking tax base as more sick people leave the workforce.

“We all know prevention is a good idea, but we are trying to convince governments of its economic necessity,” Refsum said.

She explained that many governments see healthcare spending as a “black hole.” However, TBI’s stance is that not all health spending is equal, and investing in prevention can yield significant returns compared to funding more hospitals or treatments.

Refsum also highlighted the importance of delivering preventative care through innovative, non-traditional means. Instead of relying solely on general practitioners or family doctors, she suggested providing support where people already are—online, at home, or in their communities.

“We have to think about different models of care that make better use of pharmacies, gyms, workplaces, and other local resources,” she said.

The Lancet Commission on Dementia estimates that addressing risk factors like smoking, high blood pressure, high cholesterol, obesity, and inactivity can reduce dementia risk by up to 45%.

Refsum pointed to New Zealand’s CBAX tool, a spreadsheet model with a database that helps agencies monetise impacts and conduct cost-benefit analyses. In the health sector, this tool is being used to assess people’s risk factors for certain life events, justifying investment in areas like children’s and young people’s health.

“This is a good example of using data to target prevention more effectively,” Refsum said.

Helen Rochford-Brennan (far right) participates in the "Advancing Global Collaboration for Dementia and Healthy Aging" event on October 8, 2024.
Helen Rochford-Brennan (far right) participates in the “Advancing Global Collaboration for Dementia and Healthy Aging” event on October 8, 2024. Other members of the panel include from left: Drew Holzapfel of the Davos Alzheimer’s Collaborative; Yoshimasa Tosaka of the Ministry of Health, Labour and Welfare of Japan; Hilary Evans-Newton of Alzheimer’s Research UK; and Howard Bergman of McGill University.

Rochford-Brennan also expressed hope that the conference would inspire G7 countries to listen to the needs of dementia patients and invest not only in treatments but also in the infrastructure surrounding detection, care, and ongoing support.

“The cost would be so much less if newly diagnosed people could stay at work, continue their lives, and have another 20 years of productive living,” Rochford-Brennan said. “There are so few countries in Europe with a dementia plan. We need to ensure healthcare systems provide early diagnosis and long-term, individualised support.”

Image Credits: Courtesy of Helen Rochford-Brennan, Courtesy of the Davos Alzheimer’s Collaborative, Courtesy of the Davos Alzheimer's Collaborative.

Palestinian children being getting the oral polio vaccine during the first phase of vaccinations in northern Gaza in September.

The second round of polio vaccinations for Gaza’s children are due to begin on Monday – but the World Health Organization’s (WHO) Eastern Mediterranean Region (EMRO) is assessing whether it may be affected by Israel’s renewed military activity in northern Gaza, including evacuation orders for three hospitals over the past 48 hours.

WHO EMRO officials appealed to Israel for a “humanitarian pause” to enable it to complete its polio vaccination campaign at a media briefing on Tuesday.

The first polio case in Gaza in 25 years was identified in a 10-month-old baby in August and the virus has also been detected in wastewater samples. In response, the WHO launched a mass vaccination campaign last month, which reached some 540,000 children under the age of 10 – 90% of all kids in this age group.

However, these children need a second polio vaccine within four weeks.

Dr Rick Brennan, EMRO’s regional emergency director, said that the WHO was still trying to determine how Israel’s new evacuation orders, for both the hospitals and various parts of the territory, would affect the polio vaccination campaign.

“Of course, what we need to successfully conduct the campaign is a pause in military operations. We were able to get that temporary pause for the previous round and we need that again,” said Brennan.

He added that it was “absolutely vital” to both complete the second round of vaccinations and get the cooperation of the relevant authorities to do so.

Dr Rick Brennan, WHO EMRO’s regional emergency director

“We’re working on it very hard right now,” he added.

The WHO has planned its vaccination campaign in three phases – in southern, central and northern Gaza. Brennan estimates each phase will take three days, with an extra day or two to find children who have missed out.

“We’re using a broad combination of measures: vaccinating kids in health facilities, sending teams out to communities, and working with community members to ensure that children are brought to sites where vaccinations are going on.”

Unlike the first vaccinations, children will also get vitamin A. 

“Vitamin A is very important for the immune system, particularly with the high level levels of food insecurity, with 96% of the population in Gaza at crisis levels of food insecurity,” said Brennan, describing “significantly increased rates of acute malnutrition in kids under the age of five”.

Extensive damage to population and health facilities

WHO EMRO regional director Dr Hanan Balkhy

Less than half of Gaza’s hospitals are functioning due to “damaged infrastructure, lack of fuel, supplies and human resources, and ongoing attacks”, EMRO regional director Dr Hanan Balkhy told the briefing.

Of the 15,600 requests for medical evacuations, only 5,130 have been approved, “leaving thousands of Gazans stranded without essential care”, she added.

“Twelve months of conflict in Gaza has resulted in 6% of the entire population killed or injured. Many of the injured are women and children who now face lifelong disabilities,” Balkhy said.

“Ninety percent of Gaza’s population is displaced and living in overcrowded shelters with limited access to food, water, or health care. And they are repeatedly on the move, with further evacuation orders issued over the past few days,” she added.

Describing health service delivery under such circumstances as “daunting”, Balkhy paid tribute to the health workers of Gaza “who continue to work heroically under unimaginable conditions”.

Almost 1000 health workers have been killed in the year-long conflict, according to the Gaza Health Ministry, while 289 United Nations staff  have also lost their lives in “one of the most dangerous places in which the UN and partners operate”, said Balkhy.

“For the past 12 months, WHO and its partners have repeatedly called for an end to the conflict in Gaza. However, the situation continues to escalate in the occupied Palestinian territory and across the region,” she added.

She also expressed “extreme concern” about the escalation of violence in Lebanon, with “almost 12,000 people killed or injured, and more than 540,000 people internally displaced”.

The WHO EMRO, one of the most conflict-ridden regions of the world where an estimated one in six people need humanitarian assistance, holds its annual regional committee meeting next week.

Image Credits: WHO.

Anti-government protestors in Tel Aviv call for a ceasefire and hostage deal on the 1st anniversary of the war.

Israelis in southern and northern Israel huddled in shelters under missile and rocket fire from Gaza’s Hamas and Lebanon’s Hezbollah militia. Palestinians in northern Gaza were being forced to relocate away from yet another incursion of Israeli tanks into densely populated urban areas, including Jabalia refugee camp. Lebanese in southern Lebanon fled at a thickening pace of Israeli air attacks on Hezbollah targets Monday – all in the grinding cycle of violence that marked the one year anniversary of the start of the Israel-Hamas war on October 7 2023. 

One year after the bloody Hamas rampage into Israeli villages and towns near Gaza in the early morning hours that killed almost 1,200 people, mostly Israeli civilians in one day, the war has exacted the largest death toll on Gaza Palestinians. Gaza’s Hamas-controlled Health Ministry has reported over 41,000 deaths to date – while the apocalyptic destruction of the tiny enclave’s infrastructure, including roughly half of Gaza’s hospital network, are plainly evident.

But the powerful advances of Israel’s military into Gaza have so far failed to achieve what was supposed to be the main goal of the invasion – the release of some 101 remaining Israeli hostages held by Hamas, whose chances of physical survival in harsh underground conditions are waning, against the unrelenting circle of displacement, death, disease and mental health distress.  And Monday’s memorial events, punctuated by Lebanese, Hamas and Yemenite Houthi missile and rocket fire aimed at Israeli cities and towns from north to south, highlighted the fact that Israelis are no longer immune either to the fallout of an escalating conflict – despite a much-vaunted missile defense system.

Locked in an expanding circle of fire 

Ryad Awaja, a counsellor in Palestine’s UN Mission to Geneva is applauded as he moves to a seat for member states at final World Health Assembly session on 1 June after a WHA vote to elevate Palestine’s status to that of a member state – except for voting rights.

In the diplomatic domain, Palestinians have chalked up clear gains. In early June, the Ramallah-based Palestinian Authority has obtained quasi-state recognition by the World Health Organization and the UN General Asssembly, while Israel has found itself increasingly marginalized.  That, despite the fact that on the ground, realities are harsher than ever.

The skyline of Gaza City, which only a year ago had seen a decade-long building boom of new high rise apartments, sports arenas, restaurants, malls, and even luxury hotels, is now buried in sand and rubble – under which thousands more missing Gazans may still be buried as well.  Some 1.9 million Palestinians, or 90% of Gaza’s population, have been displaced at least once over the past year, with hundreds of thousands sheltered from sweltering summer heat and bitter winter cold only by flimsy tents.  Hunger, poverty and disease have all tightened their grip, even if Hamas still wields enough control to launch missiles into Israel – 14 in total on Monday.  

Now, as the focus of Israeli wrath shifts northward, an estimated 1 million Lebanese have been displaced, mostly in just the past week, including hundreds of thousands who have fled the country, by air when they could afford it, and if not, overland into Syria. Pressure on Lebanese health and emergency services is meanwhile mounting, as Israel widened its arc of aerial bombardment from the air, complemented by a recent ground invasion. 

But despite the recent Israeli advances into Lebanon, the 68,000 Israelis who fled their homes along Israel’s northern border last October and November, still see no date of return in sight. Another 75,200 Israelis along Gaza’s southern border also remain displaced, according to data cited by the Norwegian Refugee Council, and WHO.

In both southern Lebanon and northern Israel, towns are increasingly pockmarked with craters.  Burnt out forests and fields charred from fires are visible in areas that were popular tourist areas in calmer times. And even before the recent escalation, the year-long tit for tat cycle of attacks along the Israel-Lebanese border, which began with the Gaza war, had exacted human casualties on both sides, including a dozen Druse children, struck by a Hezbollah missile on a playground in late July. 

Meanwhile, everyone in the region was waiting to see what would come of Israel’s promised retaliation on Iran – following the Islamic state’s attack last Tuesday evening, 1 October, with 180 high-speed missiles.

‘Dangerous escalation – the best medicine is peace’

WHO Director General Dr Tedros Adhanom Ghebreyesus warns of a wider regional escalation following Iran’s most recent attack on Israel.

“The Islamic republic of Iran’s attack on Israel is a dangerous escalation, with serious consequences for the region,” said WHO Director General Dr Tedros Adhanom Ghebreyesus, speaking at a WHO press conference Thursday, 3 October, just after the Iranian barrage and ahead of the October war anniversary date. 

 “WHO calls for a de-escalation of the conflict, for health care to be protected and not attacked, for access routes to be secured and supplies delivered, and for a ceasefire a political solution and peace, the best medicine is peace,”  Tedros added. 

But on the morning of 7 October, 2024, that vision seemed further than ever from reality. 

As bereaved Israeli families gathered at 6:30 a.m. Monday in a memorial ceremony at the site of the Nova music festival, where about 400 young revelers were gunned down a year ago, and others were taken hostage, Hamas fired off the first four of the day’s 14 missiles from nearby Gaza, setting off sirens as far north as Tel Aviv, where two people were wounded from falling debris. Later in the morning, six more Israelis in the country’s third largest city, Haifa, as well as Tiberias were wounded from Hezbollah missile, rocket and drone fire from southern Lebanon.  Throughout the memorial day, hundreds of thousands of Israelis in northern Israeli communities, Jews, Palestinian Arab and Druse, were forced to stay in shelters as a total of 135 Hezbollah missiles and rockets came their way.

Hospitals in Israel’s north moved critical operations underground long ago – and unlike counterparts in Gaza and Lebanon, Israel’s health system is thus “handling the pressure in the face of rocket attacks,” a WHO spokesperson told Health Policy Watch, adding, “there is immense human suffering on all sides of the conflict.  As humanitarians, our job is to help alleviate that suffering to the degree possible while urging warring parties to exercise restraint.”      

Disproportionate death toll 

The accumulation of trash and sewage during months of war exacerbates infectious disease risks in Gaza.

Restraint has been a highly contentious concept, however, from the very beginning of the conflict. 

Israel’s bombardment of Gaza, described as amongst the most intense of modern warfare in the first months of the invasion, prompted South Africa to bring charges against Israel of genocide and other war crimes in the International Court of Justice in December 2023. Israelis denounced the accusations, arguing that the huge casualties sustained in Gaza were largely due to the fact that Hamas had embedded its forces within and underneath civilian areas; it invested heavily in tunnel networks to protect its armed forces, while leaving civilians helplessly exposed.

Since 7 October 2023, more than 1000 Gaza health workers have died, according to the most recent tally by Gaza’s Hamas-controlled Health Ministry. As of 30 August, only 17 of Gaza’s 36 hospitals remain partially operable, according to WHO. And Gaza’s largest and most sophisticated health facility, Al Shifa, was virtually destroyed after being surrounded by Israelis and caught in the crosshairs of fierce gunbattles with Hamas forces over two weeks in late March. Some 21 patients died in the hospital while more than 100 patients were trapped with insufficient food and water or hygiene during Israel’s seige, according to WHO – which it denounced as illegal under international law.

Israelis, on their side, have long contended that along with schools and refugee centers, Hamas systematically embedded armed units in Gaza’s health facilities, sometimes holding or ferrying Israeli hostages there too. Around three dozen hostages were held at  Al Nassar Hospital in October and early November 2023, former Israeli hostage Sharon Aloni Cunio told CNN in January. Cunio described how she and her twin three-year-old daughters were held one of three hospital rooms, each containing about a dozen hostages, for most of their captivity and prior to their release in late November.  Her husband David still remains hostage in Gaza. 

Rising Lebanese death of emergency responders 

People gather around a bombed building in a southern suburb of Beirut.

In Lebanon, as well, where Hezbollah militias also are deeply embedded in civilian areas that also lack shelters or significant air defenses, the death toll is now rising too. Some 1,974 people, including 127 children and 261 women, have been killed by Israel since 7 October, said said Lebanon’s Minister of Public Health, Dr. Firas Al-Abyad, in a 3rd October press conference. More than 140 Lebanese ambulance workers, firefighters and paramedics also have died.

The death toll has mounted sharply during the most recent series of Israeli attacks on Hezbollah’s top leadership, including Hassan Nasrallah, killed in an Israeli aerial raid on Beirut on 27 September. That has been followed by an Israeli ground incursion into southern Lebanon – which has the stated aim of pushing Hezbollah back from the border area, so that displaced Israelis can safely return to their homes in the north.

“In southern Lebanon, 37 health facilities have been closed, while in Beirut, three hospitals have been forced to fully evacuate staff and patients, and another two were partially evacuated,” said Tedros in his remarks to the media last Thursday. [On Friday, a sudden Israeli air strike outside the gates of a hospital in Marjyoun, killed seven paramedics and forced that facility to close as well[. 

“Health and humanitarian workers, including WHO staff, have done incredible work under very difficult and dangerous conditions with limited supplies, and yet healthcare continues to come under attack in Lebanon,” Tedros added. As a result, he noted, “many health workers are not reporting to duty as they fled the areas where they work due to bombardments. 

“This is severely limiting the provision of mass trauma management and continuity of health services…. We had planned to deliver a large shipment of trauma and medical supplies tomorrow to Lebanon. Unfortunately, this has not been possible due to the almost complete closure of Beirut’s airport.  WHO calls on all partners to facilitate flights to deliver much needed life-saving supplies to Lebanon.”

Dramatically different perceptions of the war affect responses to its worst atrocities

Scenes of Gaza’s humanitarian crisis are regularly aired on TV channels from Europe to America and Asia – much less so in Israel.

On both sides, dramatically different perceptions of the reasons behind the war, and its conduct, have fueled disbelief, or indifference, to reports of attacks on civilians, on hospitals and health workers, as well as reports of abuse and atrocities on either side of the Palestinian-Israeli divide.

Despite oft-fierce criticism of Prime Minister Benjamin Netanyahu for ducking a hostage deal, Israel’s mainstream TV channels have only portrayed only a fraction of the scenes from Gaza’s humanitarian crisis, regularly played out in European and American media – not to mention Asia and the Middle East.   

Conversely, the narrative of Israeli commuities in southern Israel that were brutalized and displaced on October 7, and subsequently in the north, has continued to dominate the Israeli media, long after it was forgotten elsewhere.  Accounts of Hamas sexual violence and sexual torture of Israeli women were questioned or ignored altogether by the humanitarian community, until a visit to Israel by a UN special representative, Pramila Patten, in late January. She later told the UN Security Council that there were ‘reasonable grounds’ to believe the Israeli reports

Sharon Aloni Cunio (left) and her sister Danielle Aloni, describe their time in Hamas captivity with their children on Israel’s Channel 12 TV station, October 7.

“What I witnessed in Israel were scenes of unspeakable violence perpetrated with shocking brutality,” Patten told the Security Council at a session in March, following her interviews with nearly 3 dozen survivors and witnesses of the 7 October attacks, including released hostages, and review of extensive film footage of the attacks. It was a catalogue of the most extreme and inhumane forms of killing, torture and other horrors.”   

Inside Israel, meanwhile, allegations of sexual abuse and torture of Gazan Palestinians captured and held as prisoners at the Sde Teiman detention camp in the Negev desert, which surfaced over the summer as a result of a series of media leaks by Israeli medical doctors disturbed with what they had witnessed, were also met with widespread disbelief or denial in Israel.  

“The testimonies reveal that Palestinians currently in Israeli prisons are being subjected to harsh arbitrary violence on a frequent basis, sexual assault, humiliation and degradation, deliberate starvation, forced lack of hygiene, sleep deprivation,” and more, stated an August report by the Israeli human rights group B”Tselem. 

The late August arrest of 10 soldiers suspected of aggravated sodomy prompted a mob of right-wing Israeli protestors to attempt to overrun the army detention facility where the soldiers were being held. Five reservists whose investigation continued were later released to house arrest. In a September ruling, the country’s High Court of Justice ordered the military to abide by Israeli law and international conventions – but declined to close the facility altogether, saying conditions had improved.    

Children the ultimate victims 

Portraits of Israeli children held hostage by Hamas at a demonstration in Toronto in November 2023 – some still remain in captivity with their fate unknown.

On both sides, as well, displaced, injured and traumatized children have been the biggest victims of the war.

A recent study on the health status of some 19 Israeli children and 7 women who were among the 80 Israelis and foreign residents released from Hamas captivity in late November and early December 2023, during a brief cease-fire, found that while the group had all suffered from weight loss, hygiene-related infections and shrapnel injuries, the biggest impact was on mental health.  

“The most concerning aspects we experienced as a medical team among the returnees are psychological. Long-term follow-up is necessary to understand the medical and psychological implications of captivity,” said Dr. Noa Ziv, lead investigator for the study, published in August in the international journal Acta Paediatrica.

But here, as well, in terms of absolute numbers, it is Gaza’s children who have suffered more – with as many as 14,000 child casualties of war, according to Gaza’s Health Ministry.

Some 9 out of 10 children suffer under-nutrition risks according to a UNICEF report in early June. Sewage, unhealthy water supplies and piles of rubbish have increased the risks of infectious diseases of all kinds – particularly for children who are generally more vulnerable. That risk came to a head with the discovery of poliovirus in waste water in July, followed by the confirmation of an active case of the virus in a 10-month-old child. 

Child forages in Gaza rubble.

An initial mass vaccination campaign concluded successfully with some 560,000 children receiving the oral vaccine during a series of agreed- humanitarian pauses.  Now a second round of the WHO polio campaign is planned to commence on 14 October. 

“We have asked the Israeli authorities to consider a similar scheme that we had for the first round, something they call ‘tactical pauses’ (in fighting) during the working hours of the campaign,” said Ayadil Saparbekov, WHO lead for emergencies in the occupied Palestinian territory, in a UN press briefing in Geneva on Friday.

But with Israel stepping up its military action again in Gaza, while also preparing for a retaliatory attack on Iran, it remains to be seen if September’s successful campaign can be repeated.  

And polio is not the only threat, said UNICEF Executive Director Ted Chaiban, following a late September visit to Israel, Gaza and the West Bank.

“Since my last visit, tons of untreated solid waste have accumulated,” he reported. “I spoke to children digging in huge piles of garbage. They told me they were looking for bits of paper or cartons to light fires to cook their meals with their families. I visited Geraar Al Qudua school, which was turned into a shelter. There, in the middle of the school court, the people dug a makeshift open sewage to evacuate wastewater. With the current temperatures, these are terrible recipes for the emergence and spreading of diseases.”

Disabilities and acute rehabilitation needs

Ghazal, a 15-year-old girl with cerebral palsy, stands with her mother in a makeshift displacement camp in Deir al Balah, Gaza Strip, September 2024.

Along with the infectious disease risks, some 22,500 Gazans have have sustained life-changing injuries, including  shattered and amputated limbs, or various forms of spinal and brain trauma. And these are largely going untreated according to a WHO analysis released on 12 September. 

The WHO report refrained from providing any breakdown of casualties by gender or age.  But UNICEF says thousands of Gazan children are among those disabled since the 7 October war began, in addition to the estimated 98,000 children already living with a disability.  A recent report by Human Rights Watch drills down into the plight of disabled children living in substandard conditions and unable to access treatment. 

Another report, in The Lancet, addresses the escalating mental health crisis among Gaza’s children – in a society where 65% of the population are under the age of 25. “Constant bombardment and displacement and the loss of family members are predisposing many children to anxiety, depression, post-traumatic stress disorder (PTSD), and other adverse mental health conditions. In fact, a 2020 study showed that 53·5% of Gazan children had PTSD even before this conflict,” stated the paper published in April, and led by researchers from Egypt and Gaza, as well as Georgetown and Harvard. 

Israeli hostages – time running out 

Diminishing chances of hostage survival as 101 Israeli hostages remain in Hamas captivity.

On the Israeli side of the divide, meanwhile, an overwhelming concern remains the dwindling prospects for survival of the 101 hostages still held by Hamas or allied groups. Approximately one-third are thought to have already perished in captivity, while chances for survival of those still alive is diminishing by the day, experts warn. This includes the youngest child hostage, Kfir Bibas, who was just 9-months old when he was taken captive along with his 4-year-old brother Kfir and their mother, Shiri, on October 7 at Kibbutz Nir Oz. Hamas later said the family was  killed during an Israeli attack on the southern Gaza city of Khan Yunis, although the Bibas family still holds out hope for their survival.  

“All hostages are humanitarian cases in imminent danger. As time progresses, the number of survivors decreases sharply, potentially reaching a point where none remain alive,” stated an August report on hostage health, published by Israel’s Hostages and Missing Families Forum, marking ten months in captivity. Risks to survival range from pre-existing chronic conditions to the impacts of poor hygiene and infection exposure, lack of sunlight, exercise and adequate nutrition, leading to new diseases and chronic health conditions even in the healthiest hostages.

“It can be said with high certainty that everyone who was captured and remains alive is now suffering from various diseases and symptoms that will worsen to the point of endangering their lives, if they are not released from captivity soon,” the report stated.   

Many Israelis doubtful that a wider war will lead to hostages’ return

Israeli anti-government protestors at a demonstration in Jerusalem on Saturday night, calling for a cease-fire and hostage deal.

Against that grim picture, many or most Israelis who are connected to the hostages as family or close friends doubt that the government’s latest campaign in Lebanon will really achieve the desired effect of ramping up pressure on Hamas, Hezbollah and Iran sufficiently to bring their loved ones home alive. 

And even those Israelis who view Hezbollah as an existential threat, (and most do), see the strategic priorities of Prime Minister Netanyahu as driven largely by his political aims, which include keeping his hard-right governing coalition intact. And that aim is better further by perpetuation of the conflict, as compared to a cease-fire, including the hostages’ return – opposed by the  hardliners.  

“I don’t think that the military pressure in Lebanon will improve Israel’s negotiating position. The war in the North is a reaction which should have been taken in 2007, when Hezbollah started to break the UN Resolution 1701,” said Dita Kohl, a relative of Israeli hostage Carmel Gat, referring to the 2006 agreement in which Israel withdrew from Lebanon, in exchange for Lebanon removing Hezbollah militias from the border area, thus ending the Second Lebanon War. 

Kohl, spoke to Health Policy Watch from a bomb shelter in Tel Aviv late Monday afternoon as Israel’s central region caught another fresh volley of missile fire – including two missiles from Yemen, and a little later, from Hezbollah again. 

The family had waged a year long war for Gat’s release before the 40-year-old occupational therapist, was found dead along with five other hostages in a Hamas tunnel on 1 September – all with recent gunshot wounds to their heads.  

“The hostages are in the hands of a psychopath who does not play by any rules,” Kohl said, referring to Hamas leader Yahya Sinwar, who remains bunkered in Gaza, according to most reports,  possibly alongside other surviving captives.   

Only a few hours later, several thousand Israelis from across the country would defy the missile threats and gather for an October 7 commemoration in Tel Aviv’s  HaYarkon Park, convened by the Hostage Families Forum.  The Forum created the event as an alternative to the official state memorial ceremony, which was boycotted by most hostage families and allies – who have been blocking roads, protesting and calling for Netanyahu’s resignation over his handling of the war and management of the hostage crisis for most of the past year.    

Said Kohl, a member of the Forum, “The fundamental issue that the state of Israel and Israeli society is facing is where does the value of protecting the lives of civilians stand?”

Image Credits: HPW, UNRWA , UNICEF/Dar Al Mussawir, UNRWA , ITV/Channel 12, Doron Horowitz/FLASH90, UNICEF/UNI501989/Al-Qattaa, © 2024 Ahmad AL lulu for Human Rights Watch, Israeli Families of Hostages and Missing Persons Forum.